RGBP (Regen BioPharma) Total Liabilities : $5.37 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Total Liabilities?

Regen BioPharma's Total Liabilities for the quarter that ended in Sep. 2024 was $5.37 Mil.

Regen BioPharma's quarterly Total Liabilities increased from Mar. 2024 ($5.32 Mil) to Jun. 2024 ($5.33 Mil) and increased from Jun. 2024 ($5.33 Mil) to Sep. 2024 ($5.37 Mil).

Regen BioPharma's annual Total Liabilities declined from Sep. 2022 ($8.60 Mil) to Sep. 2023 ($5.46 Mil) and declined from Sep. 2023 ($5.46 Mil) to Sep. 2024 ($5.37 Mil).

Regen BioPharma Total Liabilities Historical Data

The historical data trend for Regen BioPharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Total Liabilities Chart

Regen BioPharma Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Total Liabilities

Get a 7-Day Free Trial

7.46

14.70

8.60

5.46

5.37

Regen BioPharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															5.46	5.40	5.32	5.33	5.37

Regen BioPharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Regen BioPharma's Total Liabilities for the fiscal year that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.372	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	5.37

Total Liabilities	=	Total Assets (A: Sep. 2024 )	-	Total Equity (A: Sep. 2024 )
	=	0.178	-	-5.194
	=	5.37

Regen BioPharma's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.372	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	5.37

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	0.178	-	-5.194
	=	5.37

Regen BioPharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RGBPP.PFD:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.